SLC5A2 and type 2 diabetes mellitus: This meta-analysis of six landmark RCTs, encompassing over 47,000 patients with type 2 diabetes, provides robust evidence that SGLT2 inhibitors significantly reduce the risk of HHF by nearly one-third compared with placebo or standard care.